Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. With over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results.
Catalent develops. With our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products.
Catalent delivers. As the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments.
Catalent supplies. Globally positioned to serve all your manufacturing and commercial packaging needs, we provide integrated solutions to take your product from design, to clinical trial, to plant, and to pharmacy.
Catalent. More products. Better treatments. Reliably supplied.™

Show more

Employee Rating

3.0More
TypePublic
HQFranklin Township, US
Founded2007
Size (employees)10,700 (est)
Websitecatalent.com
Catalent was founded in 2007 and is headquartered in Franklin Township, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Catalent

Paul Hegwood

Paul Hegwood

President, Clinical Supply Services
Laura Harding

Laura Harding

Director, Marketing & Strategy
Mike Shearer

Mike Shearer

Vice President, Global Business Development, Clinical Supply Services
Suzanne Lotowycz

Suzanne Lotowycz

Vice President, Finance
Alex McClung

Alex McClung

Vice President, Quality – Clinical Supplies
Shailesh Patel

Shailesh Patel

Global Director, Technology Strategy & Customer Integration
Show more

Catalent Office Locations

Catalent has offices in Singapore, Franklin Township, Braeside, Kakegawa and in 28 other locations
Franklin Township, US (HQ)
14 Schoolhouse Rd
Show all (32)
Report incorrect company information

Catalent Financials and Metrics

Catalent Revenue

Catalent's revenue was reported to be $1.85 b in FY, 2016 which is a 0.9% increase from the previous period.
USD

Market capitalization (9-Nov-2018)

5.5b

Closing stock price (9-Nov-2018)

37.5
Catalent's current market capitalization is $5.5 b.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

1.8b1.8b

Revenue growth, %

0%1%

Cost of goods sold

1.2b1.3b

Gross profit

598.6m587.6m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

455.8m446.6m423.0m438.0m442.2m483.7m

Cost of goods sold

299.7m294.4m301.5m318.1m335.8m

Gross profit

156.1m152.2m121.5m124.1m147.9m

Gross profit Margin, %

34%34%29%28%31%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

74.4m151.3m131.6m

Accounts Receivable

403.7m372.4m414.8m

Inventories

134.8m132.9m154.8m

Current Assets

687.5m737.5m790.2m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019

Cash

84.1m116.1m151.4m241.2m

Accounts Receivable

336.4m331.6m308.2m332.0m343.7m402.6m

Inventories

144.3m142.2m150.9m167.7m193.9m194.0m

Current Assets

637.5m653.1m691.2m727.5m928.4m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

15.2m210.3m111.2m

Depreciation and Amortization

142.9m140.8m140.6m

Cash From Operating Activities

178.3m171.8m155.3m

Cash From Investing Activities

(171.2m)(271.8m)(137.7m)(309.0m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

49.3m4.6m22.0m26.0m3.8m

Depreciation and Amortization

35.0m70.2m104.6m35.5m105.5m35.8m39.0m

Inventories

194.0m

Accounts Payable

166.8m
Show all financial metrics

Catalent Operating Metrics

Catalent's Backlog was reported to be 827.5m in FY, 2016.
FY, 2015FY, 2016

Backlog

827.60 m827.50 m

Countries

80

Facilities

33

Patents Issued

1.10 k
Show all operating metrics

Catalent Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Juniper PharmaceuticalsJuly 02, 2018$128 m

Catalent Revenue Breakdown

Embed Graph

Catalent revenue breakdown by business segment: 16.3% from Clinical Supply Services, 42.7% from Drug Delivery Solutions and 41.0% from Softgel Technologies

Report incorrect company information

Catalent Online and Social Media Presence

Embed Graph
Report incorrect company information

Catalent News and Updates

Global Blow-fill-seal Technology Market to 2023 with Market Rankings of Key Players - Catalent, Recipharm AB, Unither Pharmaceuticals & Sealed Air Corp

DUBLIN, Oct. 2, 2018 /PRNewswire/ -- The "Blow-fill-seal Technology Market by Material (Polypropylene & Polyethylene), Product (Bottles, Vials, Ampoules), End-use Industry (Pharmaceutical), & Region (North & South America, Europe, Asia Pacific, Middle East & Africa)- Global Forecast …

Catalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies

GB Sciences and Catalent tackle the first-ever formulations of APIs containing up to nine cannabinoids and terpenoids for the treatment of Parkinson's disease SWINDON, U.K., and LAS VEGAS, Sept. 26, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) and Catalent Pharma Solutions, the...

Healthcare CMO 2018 Global Market Key Players - Accellent, Boehringer Ingelheim, Catalent, DSM, Fareva, Greatbatch, Lonza......

Healthcare CMO – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2025 Posted via Industry Today. Follow us on Twitter @IndustryToday

Global Healthcare BPO Business Market 2018 | Major Kay Players – Quintiles, HCL, Cognizant, Covance, Accenture, Inventiv, Catalent, Parexel

WiseGuyRerports.com Presents “Global Healthcare BPO Business Market Size, Status and Forecast 2025” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

Clinical Trial 2018 Global Market Key Players - Patheon, Parexel International, Sharp Packaging Services, ALMAC Group, Catalent Pharma Solutions.....

Clinical Trial – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Catalent to buy Juniper Pharmaceuticals for $11.50 per share

July 3 (Reuters) - U.S. drug contract manufacturer Catalent Inc said on Tuesday it will buy Juniper Pharmaceuticals Inc for $11.50 per share in cash.
Show more
Report incorrect company information

Catalent Company Life and Culture

Report incorrect company information

Catalent Frequently Asked Questions

  • When was Catalent founded?

    Catalent was founded in 2007.

  • Who are Catalent key executives?

    Catalent's key executives are Paul Hegwood, Laura Harding and Mike Shearer.

  • How many employees does Catalent have?

    Catalent has 10,700 employees.

  • What is Catalent revenue?

    Latest Catalent annual revenue is $1.8 b.

  • What is Catalent revenue per employee?

    Latest Catalent revenue per employee is $172.7 k.

  • Who are Catalent competitors?

    Competitors of Catalent include Mast Therapeutics, Sucampo Pharmaceuticals and Amicus Therapeutics.

  • Where is Catalent headquarters?

    Catalent headquarters is located at 14 Schoolhouse Rd, Franklin Township.

  • Where are Catalent offices?

    Catalent has offices in Singapore, Franklin Township, Braeside, Kakegawa and in 28 other locations.

  • How many offices does Catalent have?

    Catalent has 32 offices.